Forty percent of 4,000 obese adults who took Arena Pharmaceuticals's lorcaserin drug for a year lost at least 5% of their body weight compared with 25% in the placebo group who lost as much, according to a study in the Journal of Clinical Endocrinology and Metabolism. The drug didn't increase the risk of heart-valve damage, but it may not reach the market due to concerns about a potential cancer risk.

Full Story:

Related Summaries